Sanofi is buying Vicebio, a biotech, that is developing vaccines for two viruses using the molecular clamp technology ...

“Vicebio’s Molecular Clamp technology introduces a purposefully simple but thoughtful approach to further improve vaccine ...

A UK company developing technology spun out of the University of Queensland is poised for growth after being acquired by ...

Sanofi is acquiring UK biotechnology company Vicebio for up to US$1.6 billion ($2.4 billion) in the largest deal involving a ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

Sanofi is paying up to US $1.6 billion for Vicebio, taking UQ’s Molecular Clamp vaccine tech global in Australia’s biggest university IP exit.

The deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu.

Breakthrough vaccine technology invented by the University of Queensland is at the centre of a landmark deal worth over $2bn struck by global pharmaceutical giant Sanofi.

Paris-based drugmaker Sanofi is acquiring U,K,-based Vicebio to gain its molecular clamp vaccine technology, with the total ...

Respiratory vaccines specialist Vicebio Ltd. is to be acquired by Sanofi SA in a $1.6 billion deal, of which $1.15 billion ...

French pharmaceutical company Sanofi said it is acquiring London-based Vicebio to expand its range of respiratory virus ...